MMP3
Stromelysin-1
As of the edition of 20 October 2026, MMP3 (stromelysin-1, UniProt P08254) has 1 drug tested at it and 1 company on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08254
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 44
- Disease areas
- Cancer; Blood and lymph; Chemically induced; Heart and blood vessels; Inherited and neonatal; Injuries; Lungs and airways; Skin and connective tissue
- Registered trials of its drugs
- 4
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Marimastat | Active | Phase 3 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 1 |
| Total on the list | 1 |